ImmVira enters clinical development of combination therapy of MVR-T3011 IT and MEK inhibitor in the United States

Shenzhen, China, April 19, 2022 /PRNewswire/ — ImmVira announced that the company has entered into a cooperation agreement with Roche to recently establish a clinical research partnership, to conduct studies in the United States on the combination therapy of ImmVira’s MVR-T3011 IT and Roche’s MEK inhibitor cobimetinib to assess the safety and efficacy of this combination strategy.

MVR-T3011, ImmVira’s proprietary 3-in-1 oncolytic herpes simplex virus (“oHSV“), is a novel genetically Modified oHSV which aims to obtain the most favorable profile of attenuated HSV-1 with replication power in tumor cells. The incorporation of two newer and well-validated exogenous genes, antibody PD-1 and IL-12, further enhances immune responses in the tumor microenvironment. Computational clinical trials of MVR-T3011 began in 2020 and are currently in Phase II in the United States and China. The single agent treatment has demonstrated a good safety profile and preliminary efficacy results.

In 2021, the research group ImmVira published a scientific article, “Improving Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with the MEK Inhibitor trametinib in Selected BRAF or KRAS Mutated Colorectal or Lung Carcinoma Models”. In vitro and live anti-tumor studies have shown that treatment with MEKi increased the oncolytic activity of HSV in BRAF V600E mutated tumor cells and that the combination treatment increased viral replication mediated by down-regulation of expression or phosphorylation of STAT1 and PKR in BRAF V600E mutated tumor cells as well as BRAF wt/KRAS mutated tumor cells. In addition, significant synergistic therapeutic efficacy has been demonstrated live for BRAF wt/KRAS mutation tumor models, when a combination of MEK inhibition and oHSV expressing PD-1 blocking antibody and IL-12.

“This combined clinical study further demonstrates the potential ability of MVR-T3011 to further extend clinical benefits to a wide range of approved treatment programs. It is also the first combination therapy other than checkpoint inhibitor of our leading oncolytic products, and the first application of scientific exploration to clinical studies. We are particularly pleased to collaborate with Roche with their leadership in industry, their global footprint and a deep pocket of established programs as well as new programs driven by the inspiring purpose of doing now what patients need next,“said Dr. Grace ZhouCEO of ImmVira.

Based on the new OvPENS drug R&D platform, ImmVira will continue to advance vector-based oncology solutions. Leveraging a unique approach to modifying the tumor environment, our pipeline of single-agent and combination programs aims to become a new generation of safer and more effective therapies to meet the increasingly complex needs of cancer patients. in the world. »

About ImmVira

ImmVira is a biotechnology company focused on the development of novel, next-generation cancer drug carriers. Our state-of-the-art engineering has created vectors that are highly oncolytic competent and ideal exogenous gene delivery mechanisms. Leveraging the intrinsic mechanism of action and modification of the tumor microenvironment, our products include replicating oncolytic herpes simplex virus, as well as non-replicating tumor exosomes and vaccines. The company has developed the science, technology and know-how to support the ongoing research, development and commercialization of the best monotherapies and combination therapies on the OvPENS (OV+ Potent, Enabling, Novel & Safe) platform.

Our clinical-stage and development-stage pipelines target a wide range of solid tumors and hematological malignancies, to be used as single-agent or combination treatment solutions for cancer patients at various stages, unresponsive to immunotherapy or patients with rare tumors, by various methods of administration, including intratumoral, as well as first-rate intravenous and intraperitoneal/pleural/bladder injections. The first three oncolytic viral products are currently in five Phase I or Phase II clinical trials in both United States and China.


Margie D. Carlisle